In a ground-breaking decision, the United States Food and Drug Administration (FDA) gave its official nod on Thursday to Paxlovid (nirmatrelvir and ritonavir tablets) - the planet's inaugural oral antiviral.
The US Food and Drug Administration (FDA) has made a historic announcement, granting approval to Paxlovid (nirmatrelvir and ritonavir tablets), the world's first oral antiviral medication. This momentous decision opens the door for the use of Paxlovid in treating adults who have mild-to-moderate Covid-19 and are at a high risk of developing severe complications, such as hospitalization or even death.
Paxlovid, developed by the renowned American pharmaceutical company Pfizer, has received approval from the US Food and Drug Administration (FDA) as the fourth drug and the first oral antiviral pill to effectively combat Covid-19 in adults. Previously, Paxlovid had been available under an emergency use authorization (EUA) in the United States.
As the pandemic transitions into the endemic phase, there is a growing consensus that oral treatments or pills have the potential to revolutionize the management of mild to moderate Covid-19 infections, representing a significant breakthrough in combating the disease.
The Medicines Patent Pool (MPP) also entered agreements with 35 global generic manufacturers to increase accessibility to affordable versions of Pfizer's oral COVID-19 treatment. These generic versions, comprising nirmatrelvir with ritonavir, will be supplied to 95 low- and middle-income countries, ensuring wider availability of this crucial medication.
In the United States, the approval of a new medication is governed by the Federal Food, Drug, and Cosmetic Act. This legislation mandates the provision of significant evidence showcasing the drug's effectiveness and safety for its intended purpose, along with other requirements.
The FDA carefully evaluates the approval of a drug by conducting a thorough benefit-risk assessment, adhering to stringent scientific standards. This meticulous process ensures that the benefits of the product outweigh the potential risks for the specific target population.
"While the pandemic has been challenging for all of us, we have made great progress mitigating the impact of COVID-19 on our lives," said Patrizia Cavazzoni, director of the FDA's Center for Drug Evaluation and Research.
“Today's approval demonstrates that Paxlovid has met the agency's rigorous standards for safety and effectiveness and that it remains an important treatment option for people at high risk for progression to severe COVID-19, including those with prior immunity.”
Please take note that the antiviral medication is neither approved nor authorized for use as a preventive measure, such as pre-exposure or post-exposure prophylaxis, against the Coronavirus.